Actovegin vs LL-37

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

Actovegin is primarily a pain management peptide, while LL-37 is used for immune support.

This page compares Actovegin and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

ActoveginLL-37
CategoryPain ManagementImmune Support
Regulatory status (US)Research use onlyCompounding (Rx) — Apr 2026
Typical dosage5-10 ml2-5 mg
Frequencymultiple weeklytwice weekly
Reported benefitsCirculation-related pain relief, tissue oxygenation, healing supportAntimicrobial activity, immune modulation, wound healing, anti-inflammatory
Reported side effectsRare allergic reactionsGenerally safe, minimal side effects

Key differences

Primary use. Actovegin is categorised under Pain Management, while LL-37 falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. Actovegin: not FDA-approved; treated as a research compound. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.

Dosing. Actovegin is typically dosed at 5-10 ml (multiple weekly). LL-37 is typically dosed at 2-5 mg (twice weekly).

Can you stack them?

Some protocols combine peptides, but stacking Actovegin and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between Actovegin and LL-37?
Actovegin is primarily a pain management peptide, while LL-37 is used for immune support. Actovegin is not FDA-approved; generally classified as a research compound, whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
What is Actovegin used for?
Hypoxic pain and healing.
What is LL-37 used for?
Antimicrobial defense peptide.
Can you take Actovegin and LL-37 together?
Some users combine peptides within a single protocol, but stacking Actovegin and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is Actovegin or LL-37 FDA-approved?
Actovegin is not FDA-approved; generally classified as a research compound. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).

Read the full articles

  • Actovegin — full monograph: mechanism, research, dosing & references
  • LL-37 — full monograph: mechanism, research, dosing & references

More Pain Management comparisons

← All peptide comparisons